/
We are a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute…
The business is unprofitable at the operating level (-1.64% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 7.4%, steady but not accelerating.
Negative free cash flow of -$28M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$151M
▲ +7.4% YoY
Net Income (TTM)
-$31M
▼ -48.7% YoY
Op. Margin
-6.94%
▲ +6.4pp YoY
ROIC
-23.79%
▲ +3.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$21M
▼ -15.2% YoY
Op. Cash Flow (TTM)
-$20M
▼ -22.5% YoY
Net Debt
-$11M
Net Cash Position
Cash & Equiv.
$45M
5Y CAGR: +11.8%
Continue Research